The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study

Figures & data

Table 1 Demographics by Obese/Non-Obese

	Non-Obese (N=100)	Obese (N=54)	Total (N=154)	p value
Gender				0.024
F	42 (42.0%)	33 (61.1%)	75 (48.7%)
M	58 (58.0%)	21 (38.9%)	79 (51.3%)
Age at diagnosis				0.003
18–39	54 (54.0%)	18 (33.3%)	72 (46.8%)
40–59	34 (34.0%)	18 (33.3%)	52 (33.8%)
≥60	12 (12.0%)	18 (33.3%)	30 (19.5%)
ALL subtype				0.434
B Cell	76 (76.0%)	44 (81.5%)	120 (77.9%)
T Cell	24 (24.0%)	10 (18.5%)	34 (22.1%)
Hyperleucocytosis at Dx				0.862
Missing	9	3	12
No	69 (75.8%)	38 (74.5%)	107 (75.4%)
Yes	22 (24.2%)	13 (25.5%)	35 (24.6%)
ECOG performance score				0.575
0	24 (24.0%)	8 (14.8%)	32 (20.8%)
1	54 (54.0%)	31 (57.4%)	85 (55.2%)
2	16 (16.0%)	11 (20.4%)	27 (17.5%)
3	6 (6.0%)	4 (7.4%)	10 (6.5%)
Cytogenetic risk group				0.126
Standard	8 (8.0%)	1 (1.9%)	9 (5.8%)
Intermediate	52 (52.0%)	24 (44.4%)	76 (49.4%)
High	40 (40.0%)	29 (53.7%)	69 (44.8%)
CNSL at DX				0.381
No	93 (93.0%)	48 (88.9%)	141 (91.6%)
Yes	7 (7.0%)	6 (11.1%)	13 (8.4%)
Induction regimen				0.396
HyperCVAD based	46 (46.0%)	21 (38.9%)	67 (43.5%)
BFM based	54 (54.0%)	33 (61.1%)	87 (56.5%)
Diagnosis cohort				0.958
Dx 1994–2004	44 (44.0%)	24 (44.4%)	68 (44.2%)
Dx 2005–2015	56 (56.0%)	30 (55.6%)	86 (55.8%)

Table 2 Cox Proportional Hazards Models-Time to Death Comparing BMI Groups Adjusting for Baseline Variables

Parameters	Reference	HR (95% CI)	p-value
BMI group adjusting for B/T cell	Non-obese	1.55 (0.99, 2.43)	0.054
BMI group adjusting for age group	Non-obese	1.41 (0.87, 2.28)	0.165
BMI group adjusting for cytogenetic risk group	Non-obese	1.45 (0.92, 2.27)	0.106
BMI group adjusting for gender	Non-obese	1.68 (1.07, 2.63)	0.024
BMI group adjusting for hyperleucocytosis	Non-obese	1.55 (0.97, 2.47)	0.066
BMI group adjusting for ECOG status	Non-obese	1.61 (1.03, 2.52)	0.038
BMI group adjusting for CNSL	Non-obese	1.61 (1.03, 2.51)	0.035
BMI group adjusting for induction regimen	Non-obese	1.57 (1.01, 2.45)	0.046

Figure 1 Time to complete response (1 year).

Figure 2 (A) Overall survival by BMI group (non-obese vs obese). (B) Event-free survival by BMI group (non-obese vs obese). (C) Relapse by BMI group (non-obese vs obese). Patients with prior BMT are censored.

Figure 3 (A) T-cell ALL overall survival by BMI group (non-obese vs obese). (B) T-cell ALL event-free survival by BMI group (non-obese vs obese).

Figure 4 (A) B-cell ALL overall survival by BMI group (non-obese vs obese). (B) B-cell ALL event-free survival by BMI group (non-obese vs obese).